Table 1.
Baseline characteristics for treatment groups
| Placebo | Low-dose testosteronea | High-dose testosteroneb | |
|---|---|---|---|
| Study 1 | |||
| No. of subjects | 8 | 6 | 8 |
| Age (years) | 67.5 (4.1) | 62.3 (2.3) | 64.6 (3.9) |
| Weight (kg) | 79.8 (8.5) | 76.3 (7.0) | 85.8 (7.7) |
| Body mass index (kg/m2) | 26.7 (2.2) | 27.0 (1.9) | 27.1 (1.0) |
| Free testosterone (pg/mL) | 8.79 (2.01) | 8.92 (1.53) | 10.16 (1.74) |
| Total testosterone (nmol/L) | 13.64 (2.87) | 14.53 (2.52) | 15.51 (2.73) |
| Plasma P3NP (ng/L) | 3.33 (0.95) | 3.08 (0.55) | 3.13 (0.64) |
| Study 2 | |||
| No. of subjects | 9 | 9 | 10 |
| Age (years) | 30.0 (6.1) | 26.2 (6.3) | 30.1 (5.1) |
| Weight (kg) | 81.7 (9.2) | 83.7 (11.2) | 81.6 (11.9) |
| Body mass index (kg/m2) | 25.0 (2.2) | 26.7 (2.6) | 24.9 (2.3) |
| Free testosterone (pg/mL) | 17.14 (2.84) | 16.09 (3.78) | 17.80 (3.74) |
| Total testosterone (nmol/L) | 19.79 (3.00) | 16.26 (4.49) | 19.50 (5.10) |
| Plasma P3NP (ng/L) | 3.51 (0.76) | 3.69 (0.80) | 3.82 (0.66) |
Mean (standard deviation)
aFor study 1, low = testosterone 100 mg. For study 2, low = testosterone 200 mg.
bFor study 1, high = testosterone 300 mg. For study 2, high = testosterone 600 mg.